Conference Day Two: Wednesday, May 1, 2024
7:30 am Morning Coffee & Registration
Navigating the Potential of LNP to Understand the Therapeutic Applications to Uncover
8:30 am Chair’s Opening Remarks
8:45 am Capitalizing on CAR-T Therapy as the Next Step in the LNP Development Journey
Synopsis
- Revolutionizing the utility of LNPs as the field make significant strides into the cell therapy world
- Applying LNP understanding to transfecting primary human T cells in the cell therapy workflow
- Evaluating the potential of LNPs as the ‘go-to’ delivery vehicle for CAR-T therapies with a comparison of current vehicles of choice
9:15 am Panel Discussion: The Diary of an LNP Biotech CEO: From Concept to Clinic
Synopsis
- Revealing the steps taken to transition from stealth to established to develop LNPs at a biotechnology company
- Outlining the priority action points collectively as an industry to drive progress in 2024
- Discussing interactions with regulatory bodies and the early planning steps taken in anticipation of future submissions
10:00 am Morning Break & Refreshments
Honing Research into Ligand & PEG Molecules to Maximize LNP Delivery Potential
Download the Full Event Guide for more details
11.15 am Overview of USP’s Standard Setting Process and Evolving Approaches to Excipient Standard Setting in Support of Early-Stage Drug Development
Catherine Sheehan, Senior Director, Foods & Excipients - Global Science & Standards, United States Pharmacopeia (USP)
11.45 am The Impact of Lipid-Lipid Interactions on Lipid Nanoparticles
Sutapa Barua, Senior Principal Scientist, Pfizer
12.15 pm Ask the Speakers
12:45 pm Networking Lunch Break
Evaluating Holistic Methods to Screen for LNP Biodistribution to Drive LNPs to the Previously Unreachable
Download the Full Event Guide for more details
2.00 pm Advancing LNP Screening to Incorporate Automated, High-Throughput Readouts
Marine Hatit, Senior Scientist I, LNP Discovery Lead, Prime Medicine
2.30 pm Ask the Speakers
Your unique opportunity to ask the speakers your burning questions from the previous sessions in a dedicated Q&A session
3:15 pm Afternoon Networking Break
Reviewing the LNP Novel Payloads Across Current Research & Advanced Routes of Administration
4:15 pm Combining p53 mRNA Nanotherapy with Immune Checkpoint Blockade for Liver Cancer
Synopsis
- Outlining how immunotherapy with immune checkpoint blockade (ICB) shows limited benefits in hepatocellular carcinoma (HCC) and other cancers, mediated in part by the immunosuppressive tumour microenvironment (TME)
- Examining the effects of restoring p53 expression on the immune TME and ICB efficacy
- Inducing p53 expression in HCC models effectively, eliciting a global reprogramming of cellular and molecular components of the immune TME, combining with ICB
4:45 pm Analyzing the Optimal Route of Administration in Relation to LNP Design, Target Organ & Disease Indication
Synopsis
- Addressing the breadth of administration routes available for LNPs, including intravenous, intramuscular, subcutaneous and inhalation routes
- Evaluating the resulting antibody response to LNP administration following differing administration
- Correlating the target organ and disease indication severity with route of administration to maximise precise biodistribution